Effect of PCSK9 Inhibitor Usage on Coronary Endothelial Dysfunction in Patients With Hypercholesterolemia after Coronary Stenting: The CuVIC-2 Trial
The CuVIC-2 trial demonstrated that in patients after coronary stenting who presented with LDL-C ≧70 mg/dL receiving high-intensity or maximally tolerated statins with or without ezetimibe, the addition of evolocumab did not ameliorate coronary endothelial dysfunction, according to a study presented by Dr. Tetsuya Matoba, Kyushu University, Japan, in the Late Breaking Clinical Trials session at CVIT 2024.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.